Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective To compare accuracy of serum human epididymis protein 4 (HE4) levels with cancer antigen 125 (CA-125) levels as biomarkers for ovarian cancer. Methods The study population included 94 Korean women, including 32 patients with a diagnosis of ovarian cancer and 62 patients with a diagnosis of benign ovarian tumor. All diagnoses were confirmed by histopathological analysis. Serum HE4 levels were assessed using an HE4 enzyme immunoassay, which were performed according to the manufacturer’s instructions. Serum CA-125 levels were determined using a Modular analytics E170 module. Results The median serum CA-125 and HE4 levels were significantly higher in patients with ovarian cancer than those with other benign tumors (CA-125, 394.1 U/mL vs. 22.7 U/mL; HE4, 56.7 pM vs. 18.5 pM; P < 0.05 in both). An additional comparison revealed that the patients with endometriosis had greater median serum CA-125 levels than those with other benign ovarian tumors (32.0 U/mL vs. 17.9 U/mL, P = 0.03). Conversely, the median serum HE4 levels were similar among the two benign ovarian tumor groups, with no statistically significant difference observed (19.0 pM vs. 18.2 pM, P = 0.49). The receiver operating characteristics curve analysis for the benign ovarian tumor and ovarian cancer patients showed that HE4 showed a greater area under the curve with borderline significance when compared with CA-125 in both groups (0.93 vs. 0.85). Conclusion Serum HE4 levels may not only allow for the detection of ovarian cancer, but also allow for better differentiation of cases of ovarian cancer versus other benign ovarian tumors compared with serum CA-125.
Abstract
Objective To compare accuracy of serum human epididymis protein 4 (HE4) levels with cancer antigen 125 (CA-125) levels as biomarkers for ovarian cancer. Methods The study population included 94 Korean women, including 32 patients with a diagnosis of ovarian cancer and 62 patients with a diagnosis of benign ovarian tumor. All diagnoses were confirmed by histopathological analysis. Serum HE4 levels were assessed using an HE4 enzyme immunoassay, which were performed according to the manufacturer’s instructions. Serum CA-125 levels were determined using a Modular analytics E170 module. Results The median serum CA-125 and HE4 levels were significantly higher in patients with ovarian cancer than those with other benign tumors (CA-125, 394.1 U/mL vs. 22.7 U/mL; HE4, 56.7 pM vs. 18.5 pM; P < 0.05 in both). An additional comparison revealed that the patients with endometriosis had greater median serum CA-125 levels than those with other benign ovarian tumors (32.0 U/mL vs. 17.9 U/mL, P = 0.03). Conversely, the median serum HE4 levels were similar among the two benign ovarian tumor groups, with no statistically significant difference observed (19.0 pM vs. 18.2 pM, P = 0.49). The receiver operating characteristics curve analysis for the benign ovarian tumor and ovarian cancer patients showed that HE4 showed a greater area under the curve with borderline significance when compared with CA-125 in both groups (0.93 vs. 0.85). Conclusion Serum HE4 levels may not only allow for the detection of ovarian cancer, but also allow for better differentiation of cases of ovarian cancer versus other benign ovarian tumors compared with serum CA-125.
참고문헌 (29)
- Ozols RF, "Recurrent ovarian cancer : evidence-based treatment", J Clin Oncol, 20, pp.1161~1163 (2002)
- Parkin DM, "Estimates of the worldwide incidence of 25 major cancers in 1990", Int J Cancer, 80, pp.827~841 (1999)
- Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
- 박보영, "Epidemiological characteristics of ovarian cancer in Korea", Journal of Gynecologic Oncology, 21(4), pp.241~247 (2010), 대한부인종양학회
- "Cancer incidence trend analysis 1999-2007" (2012)[URL]
- [URL]
- Medeiros LR, "Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review", Eur J Obstet Gynecol Reprod Biol, 142, pp.99~105 (2009)
- Tian C, "CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study", Cancer, 115, pp.1395~1403 (2009)
- Urban N, "Ovarian cancer screening", Hematol Oncol Clin North Am, 17, pp.989~1005 (2003)
- Chen DX, "Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses", Obstet Gynecol, 72, pp.23~27 (1988)
- Bast RC Jr, "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer", N Engl J Med, 309, pp.883~887 (1983)
- Jacobs I, "The CA 125 tumour-associated antigen: a review of the literature", Hum Reprod, 4, pp.1~12 (1989)
- Kirchhoff C., "Molecular characterization of epididymal proteins", Rev Reprod, 3, pp.86~95 (1998)
- Clauss A, "A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein", Biochem J, 368, pp.233~242 (2002)
- Bingle L, "The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms", Oncogene, 21, pp.2768~2773 (2002)
- Hellstrom I, "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma", Cancer Res, 63, pp.3695~3700 (2003)
- Galgano MT, "Comprehensive analysis of HE4 expression in normal and malignant human tissues", Mod Pathol, 19, pp.847~853 (2006)
- Montagnana M, "The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?", Clin Chem Lab Med, 49, pp.521~525 (2011)
- Abdel-Azeez HA, "HE4 and mesothelin : novel biomarkers of ovarian carcinoma in patients with pelvic masses", Asian Pac J Cancer Prev, 11, pp.111~116 (2010)
- Havrilesky LJ, "Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence", Gynecol Oncol, 110, pp.374~382 (2008)
- Rein BJ, "Potential markers for detection and monitoring of ovarian cancer", J Oncol, 2011, pp.475983~ (2011)
- Moore RG, "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass", Gynecol Oncol, 108, pp.402~408 (2008)
- Huhtinen K, "Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts", Br J Cancer, 100, pp.1315~1319 (2009)
- Karolina Partheen, "Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass", Journal of Gynecologic Oncology, 22(4), pp.244~252 (2011), 대한부인종양학회
- Bae DH, "A comparative study between pulsatility index, new scoring system and CA-125 in detecting malignant ovarian tumor", Korean J Gynecol Oncol Colposc, 4, pp.32~39 (1993)
- Nam JH, "Preoperative tumor marker levels in differentiating malignant from benign tumors in with pelvic masses", Korean J Gynecol Oncol Colposc, 3, pp.1~9 (1992)
- 황종윤, "Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer", Journal of Gynecologic Oncology, 20(3), pp.169~175 (2009), 대한부인종양학회
- Kim YM, "Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population", Clin Chem Lab Med, 49, pp.527~534 (2011)
- Park Y, "Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer", Int J Cancer, 130, pp.1136~1144 (2012)